Entrada Therapeutics Inc (TRDA) Key Ratios
$7.12
As on 04-Sep-2026 13:36EDT
Market cap
$273 Mln
Revenue (TTM)
$5 Mln
P/E Ratio
--
P/B Ratio
1.2
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 2.63 | -53.95 | -94.10 | -52.39 | -- |
| EBIT | -7.68 | 0.46 | -114.50 | -181.38 | -223.42 |
| Net Profit | -7.67 | 0.79 | -126.00 | -123.30 | -223.59 |
| EPS | -6.69 | 2.86 | -122.70 | -22.92 | -183.12 |
| Book Value | -- | -- | -25.69 | 2.96 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -173.65 | -226.49 | -3,520.25 | -561.84 | 31.54 |
| Net Margin
| -- | 161,522.58 | -3,537.73 | -- | -- |
| Return on equity
| -7.50 | -19.13 | -61.45 | -39.13 | 19.56 |
| Return on Capital
| -6.67 | -18.30 | -- | -34.03 | 16.44 |
| Return on Assets
| -6.83 | -16.10 | -42.03 | -31.81 | 13.18 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.17 | 0.14 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
--
|
-34.03
|
16.44
|
-2.43
|
-32.56
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-61.45
Lower than Peers by 21.05
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
-61.45
|
-39.13
|
19.56
|
-2.94
|
-34.21
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-42.03
Lower than Peers by 11.05
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
-42.03
|
-31.81
|
13.18
|
-1.85
|
-31.35
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
-3,520.25
Lower than Peers by 3,436.63
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
-3,520.25
|
-561.84
|
31.54
|
9.34
|
-384.99
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
-3,537.73
Lower than Peers by 3,445.06
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
-3,537.73
|
-565.48
|
31.13
|
-5.18
|
-346.23
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
-94.10
Lower than Peers by 148.06
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
-94.10
|
-0.88
|
0.63
|
4.11
|
--
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
-114.50
Lower than Peers by 113.70
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
-114.50
|
-314.82
|
451.47
|
112.40
|
-90.21
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
-126.00
Lower than Peers by 118.70
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
-126.00
|
-319.04
|
1,081.69
|
92.36
|
-74.66
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
-122.70
Lower than Peers by 137.35
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
-122.70
|
-3.28
|
8.61
|
0.93
|
-0.16
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
-39.78
Lower than Peers by 29.60
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
-39.78
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
--
|
0.17
|
0.14
|
0.28
|
0.12
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.02
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
0.02
|
0.01
|
0.02
|
0.03
|
0.04
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
10.89
Higher than Peers by 5.08
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
10.89
|
12.53
|
11.15
|
2.33
|
9.55
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
10.89
Higher than Peers by 5.19
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
10.89
|
--
|
--
|
2.33
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
--
|
--
|
--
|
--
|
-36.95
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
17.41
Lower than Peers by 1.73
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
17.41
|
10.14
|
1.75
|
4.56
|
--
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
0.01
Lower than Peers by 0.05
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
0.01
|
0.06
|
0.42
|
0.36
|
0.09
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
--
|
44.95
|
8.28
|
16.64
|
12.61
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
--
|
--
|
0.00
|
0.00
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
--
|
291.95
|
364.77
|
16.94
|
645.31
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
--
|
--
|
-356.48
|
-0.30
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
--
|
-2.96
|
11.34
|
-75.32
|
-4.85
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
1.17
Lower than Peers by 4.01
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
1.17
|
1.39
|
1.74
|
2.08
|
1.99
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
1.58
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
1.58
|
-1.27
|
5.46
|
14.75
|
-2.74
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
273
Higher than Peers by 127
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
273
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|